Eli Lilly and Company (LLY)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 1,174.60 |
|---|---|
| 52-week range | 685.50 – 1,175.80 |
| Return, 1 month / 3 months | +14.1% / +15.0% |
| Return, 1 year / 3 years | +69.8% / +117.1% |
| Trend | Uptrend |
| RSI (14) | 67 |
| Volatility (1 year) | 34.0% |
| Worst drawdown (1 year) | -22.9% |
| Average daily value traded | 1.28M EUR |
| Dividend yield | 0.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Eli Lilly and Company is a pharmaceutical company based in Indianapolis in the United States. It researches, develops and makes prescription medicines for people with diabetes, obesity, cancer, immune disorders and mental health conditions. Its products include insulin treatments, injectable therapies that regulate blood sugar and appetite, and drugs for oncology and immunology. The company supplies hospitals, clinics, pharmacies and healthcare providers in markets around the world, and it also sells animal health products through a separate business.
The shares are listed on the XETRA Stock Exchange in Germany under the code LLY, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Eli Lilly and Company (LLY) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 1,174.60 on 22 October 2026.
Its price-based Market X-Ray is 77 out of 100 (a strong price profile), ranking 36 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 69.8% and over the last three months it rose 15.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 91 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 25.0% | ||
| From 52-week high | 0.0% | ||
| Momentum | 89 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 15.0% | ||
| 6-month return | 50.5% | ||
| 12-month return, skipping the last month | 48.8% | ||
| Stability (higher is calmer) | 63 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 34.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.9% | ||
| Liquidity | 75 · Strong | Trades actively. | |
| Average daily value traded | 1.28M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 48 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.5% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.6% |
|---|---|
| 1 month | +14.1% |
| 3 months | +15.0% |
| 6 months | +50.5% |
| 1 year | +69.8% |
| 3 years | +117.1% |
| 5 years | +490.7% |
Signals
| 50-day / 200-day average | 1,038.43 / 939.32 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 32.38 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Aug 2026 | USD 1.5388 |
| 15 May 2026 | USD 1.5388 |
| 13 Feb 2026 | USD 1.5388 |
| 14 Nov 2025 | USD 1.3343 |
| 15 Aug 2025 | USD 1.3343 |
| 16 May 2025 | USD 1.3343 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.